Cargando…
Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems
Due to their distinctive structural features, lyotropic nonlamellar liquid crystalline nanoparticles (LCNPs), such as cubosomes and hexosomes, are considered effective drug delivery systems. Cubosomes have a lipid bilayer that makes a membrane lattice with two water channels that are intertwined. He...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224018/ https://www.ncbi.nlm.nih.gov/pubmed/37242663 http://dx.doi.org/10.3390/pharmaceutics15051421 |
_version_ | 1785050077610377216 |
---|---|
author | Leu, Jassica S. L. Teoh, Jasy J. X. Ling, Angel L. Q. Chong, Joey Loo, Yan Shan Mat Azmi, Intan Diana Zahid, Noor Idayu Bose, Rajendran J. C. Madheswaran, Thiagarajan |
author_facet | Leu, Jassica S. L. Teoh, Jasy J. X. Ling, Angel L. Q. Chong, Joey Loo, Yan Shan Mat Azmi, Intan Diana Zahid, Noor Idayu Bose, Rajendran J. C. Madheswaran, Thiagarajan |
author_sort | Leu, Jassica S. L. |
collection | PubMed |
description | Due to their distinctive structural features, lyotropic nonlamellar liquid crystalline nanoparticles (LCNPs), such as cubosomes and hexosomes, are considered effective drug delivery systems. Cubosomes have a lipid bilayer that makes a membrane lattice with two water channels that are intertwined. Hexosomes are inverse hexagonal phases made of an infinite number of hexagonal lattices that are tightly connected with water channels. These nanostructures are often stabilized by surfactants. The structure’s membrane has a much larger surface area than that of other lipid nanoparticles, which makes it possible to load therapeutic molecules. In addition, the composition of mesophases can be modified by pore diameters, thus influencing drug release. Much research has been conducted in recent years to improve their preparation and characterization, as well as to control drug release and improve the efficacy of loaded bioactive chemicals. This article reviews current advances in LCNP technology that permit their application, as well as design ideas for revolutionary biomedical applications. Furthermore, we have provided a summary of the application of LCNPs based on the administration routes, including the pharmacokinetic modulation property. |
format | Online Article Text |
id | pubmed-10224018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102240182023-05-28 Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems Leu, Jassica S. L. Teoh, Jasy J. X. Ling, Angel L. Q. Chong, Joey Loo, Yan Shan Mat Azmi, Intan Diana Zahid, Noor Idayu Bose, Rajendran J. C. Madheswaran, Thiagarajan Pharmaceutics Review Due to their distinctive structural features, lyotropic nonlamellar liquid crystalline nanoparticles (LCNPs), such as cubosomes and hexosomes, are considered effective drug delivery systems. Cubosomes have a lipid bilayer that makes a membrane lattice with two water channels that are intertwined. Hexosomes are inverse hexagonal phases made of an infinite number of hexagonal lattices that are tightly connected with water channels. These nanostructures are often stabilized by surfactants. The structure’s membrane has a much larger surface area than that of other lipid nanoparticles, which makes it possible to load therapeutic molecules. In addition, the composition of mesophases can be modified by pore diameters, thus influencing drug release. Much research has been conducted in recent years to improve their preparation and characterization, as well as to control drug release and improve the efficacy of loaded bioactive chemicals. This article reviews current advances in LCNP technology that permit their application, as well as design ideas for revolutionary biomedical applications. Furthermore, we have provided a summary of the application of LCNPs based on the administration routes, including the pharmacokinetic modulation property. MDPI 2023-05-06 /pmc/articles/PMC10224018/ /pubmed/37242663 http://dx.doi.org/10.3390/pharmaceutics15051421 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Leu, Jassica S. L. Teoh, Jasy J. X. Ling, Angel L. Q. Chong, Joey Loo, Yan Shan Mat Azmi, Intan Diana Zahid, Noor Idayu Bose, Rajendran J. C. Madheswaran, Thiagarajan Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems |
title | Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems |
title_full | Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems |
title_fullStr | Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems |
title_full_unstemmed | Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems |
title_short | Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems |
title_sort | recent advances in the development of liquid crystalline nanoparticles as drug delivery systems |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224018/ https://www.ncbi.nlm.nih.gov/pubmed/37242663 http://dx.doi.org/10.3390/pharmaceutics15051421 |
work_keys_str_mv | AT leujassicasl recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT teohjasyjx recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT lingangellq recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT chongjoey recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT looyanshan recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT matazmiintandiana recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT zahidnooridayu recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT boserajendranjc recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems AT madheswaranthiagarajan recentadvancesinthedevelopmentofliquidcrystallinenanoparticlesasdrugdeliverysystems |